Avalo Therapeutics (AVTX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $11.27, -6.16% vs the prior close of $12.01.
- Volume 971.07K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
AVTX slides 6.2% to $11.27, a 52-week low. Closed at $11.27, -6.16% vs the prior close of $12.01. Day range $11.23–$12.05, opened at $12.05.
AVTX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — AVTX slides 6.2% to $11.27, a 52-week low
- Closed at $11.27, -6.16% vs the prior close of $12.01. Day range $11.23–$12.05, opened at $12.05.
- Volume was 971.07K shares, 1.0x its 50-day average of 955.81K.
- Price is -33.6% vs its 50-day average ($16.98) and -31.5% vs its 200-day average ($16.44).
- 52-week range $11.23–$24.27; today's close sits at 0% of that range, 53.6% below the 52-week high.
Oct 15, 2026 — AVTX rises 1.4% to $12.01
- Closed at $12.01, +1.44% vs the prior close of $11.84. Day range $11.70–$12.35, opened at $11.93.
- Volume was 936.30K shares, 1.0x its 50-day average of 951.77K.
- Price is -29.9% vs its 50-day average ($17.13) and -27.1% vs its 200-day average ($16.48).
- 52-week range $11.58–$24.27; today's close sits at 3% of that range, 50.5% below the 52-week high.
Oct 14, 2026 — AVTX dips 1.4% to $11.84, a 52-week low, 3 down days in a row
- Closed at $11.84, -1.42% vs the prior close of $12.01. Day range $11.58–$12.12, opened at $11.90.
- Volume was 1.24M shares, 1.3x its 50-day average of 950.18K.
- Price is -31.4% vs its 50-day average ($17.26) and -28.3% vs its 200-day average ($16.51).
- 52-week range $11.58–$24.27; today's close sits at 2% of that range, 51.2% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — AVTX slides 9.3% to $12.01, a 52-week low
- Closed at $12.01, -9.29% vs the prior close of $13.24. Day range $11.99–$13.23, opened at $13.23.
- Volume was 1.65M shares, 1.8x its 50-day average of 928.65K.
- Price is -31.0% vs its 50-day average ($17.40) and -27.4% vs its 200-day average ($16.54).
- 52-week range $11.99–$24.27; today's close sits at 0% of that range, 50.5% below the 52-week high.
Oct 12, 2026 — AVTX slides 3.0% to $13.24, a 3-month low
- Closed at $13.24, -3.00% vs the prior close of $13.65. Day range $13.13–$13.69, opened at $13.56.
- Volume was 502.80K shares, 0.5x its 50-day average of 937.07K — lighter than usual.
- Price is -24.4% vs its 50-day average ($17.52) and -20.1% vs its 200-day average ($16.58).
- 52-week range $12.51–$24.27; today's close sits at 6% of that range, 45.4% below the 52-week high.
Oct 9, 2026 — AVTX rises 1.6% to $13.65
- Closed at $13.65, +1.64% vs the prior close of $13.43. Day range $13.35–$13.82, opened at $13.42.
- Volume was 648.60K shares, 0.7x its 50-day average of 942.80K.
- Price is -22.5% vs its 50-day average ($17.62) and -17.8% vs its 200-day average ($16.60).
- 52-week range $12.51–$24.27; today's close sits at 10% of that range, 43.8% below the 52-week high.
Oct 8, 2026 — AVTX dips 1.1% to $13.43, a 3-month low, 4 down days in a row
- Closed at $13.43, -1.10% vs the prior close of $13.58. Day range $12.77–$13.60, opened at $13.45.
- Volume was 990.40K shares, 1.1x its 50-day average of 938.79K.
- Price is -24.3% vs its 50-day average ($17.73) and -19.3% vs its 200-day average ($16.63).
- 52-week range $12.51–$24.27; today's close sits at 8% of that range, 44.7% below the 52-week high.
- That makes 4 straight losses.
Oct 7, 2026 — AVTX ends flat (-0.1%) to $13.58, a 3-month low, 3 down days in a row
- Closed at $13.58, -0.07% vs the prior close of $13.59. Day range $13.30–$13.98, opened at $13.43.
- Volume was 719.00K shares, 0.8x its 50-day average of 940.72K.
- Price is -23.9% vs its 50-day average ($17.84) and -18.5% vs its 200-day average ($16.66).
- 52-week range $12.51–$24.27; today's close sits at 9% of that range, 44.0% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — AVTX slides 6.9% to $13.59, a 3-month low
- Closed at $13.59, -6.92% vs the prior close of $14.60. Day range $13.23–$14.58, opened at $14.58.
- Volume was 955.60K shares, 1.0x its 50-day average of 944.98K.
- Price is -24.3% vs its 50-day average ($17.96) and -18.5% vs its 200-day average ($16.68).
- 52-week range $12.51–$24.27; today's close sits at 9% of that range, 44.0% below the 52-week high.
Oct 5, 2026 — AVTX dips 2.6% to $14.60, a 3-month low
- Closed at $14.60, -2.60% vs the prior close of $14.99. Day range $14.39–$15.09, opened at $15.09.
- Volume was 736.80K shares, 0.8x its 50-day average of 946.25K.
- Price is -19.3% vs its 50-day average ($18.08) and -12.6% vs its 200-day average ($16.71).
- 52-week range $12.51–$24.27; today's close sits at 18% of that range, 39.8% below the 52-week high.
Oct 2, 2026 — AVTX ends flat (+0.3%) to $14.99
- Closed at $14.99, +0.27% vs the prior close of $14.95. Day range $14.31–$15.16, opened at $15.05.
- Volume was 948.50K shares, 1.0x its 50-day average of 937.83K.
- Price is -17.4% vs its 50-day average ($18.16) and -10.4% vs its 200-day average ($16.73).
- 52-week range $12.41–$24.27; today's close sits at 22% of that range, 38.2% below the 52-week high.
AVTX latest news & SEC filings
Every SEC filing by or about AVTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Sullivan Christopher Ryan converted options/RSUs into 12,394 shares at $9.88 (≈$122.45K) on Sep 16, 2026; now holds 52,294
- Sullivan Christopher Ryan sold 12,394 shares at $16.33 (≈$202.44K) on Sep 16, 2026; now holds 39,900
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Sullivan Christopher Ryan sold 10,185 shares at $17.62 (≈$179.46K) on Sep 10, 2026
- Sullivan Christopher Ryan sold 10,185 shares at $17.62 (≈$179.46K) on Sep 10, 2026
- Sullivan Christopher Ryan sold 10,185 shares at $17.62 (≈$179.46K) on Sep 10, 2026
- Sullivan Christopher Ryan sold 10,185 shares at $17.62 (≈$179.46K) on Sep 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Doyle Mittie sold 679 shares at $20.00 (≈$13.58K) on Aug 28, 2026
- Doyle Mittie sold 679 shares at $20.00 (≈$13.58K) on Aug 28, 2026
- Doyle Mittie sold 679 shares at $20.00 (≈$13.58K) on Aug 28, 2026
- Doyle Mittie sold 679 shares at $20.00 (≈$13.58K) on Aug 28, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade AVTX
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, May 7, 2026, Mar 23, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.00% (largest 9.3%). That is a volatile stock.
- Liquidity: about 1.02M shares (≈$11.45M) trade per day on average.
- 52-week position: $11.27 vs a range of $11.23–$24.27 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Christopher Ryan Sullivan sold 12,394 shares on Sep 16, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 6, 2026; 8-K Jun 23, 2026.
- Share count: 53.63M shares outstanding (Aug 3, 2026), +307.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
AVTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 12.05 | 12.05 | 11.23 | 11.27 | 971.07K |
| Oct 15, 2026 | 11.93 | 12.35 | 11.70 | 12.01 | 936.30K |
| Oct 14, 2026 | 11.90 | 12.12 | 11.58 | 11.84 | 1.24M |
| Oct 13, 2026 | 13.23 | 13.23 | 11.99 | 12.01 | 1.65M |
| Oct 12, 2026 | 13.56 | 13.69 | 13.13 | 13.24 | 502.80K |
| Oct 9, 2026 | 13.42 | 13.82 | 13.35 | 13.65 | 648.60K |
| Oct 8, 2026 | 13.45 | 13.60 | 12.77 | 13.43 | 990.40K |
| Oct 7, 2026 | 13.43 | 13.98 | 13.30 | 13.58 | 719.00K |
| Oct 6, 2026 | 14.58 | 14.58 | 13.23 | 13.59 | 955.60K |
| Oct 5, 2026 | 15.09 | 15.09 | 14.39 | 14.60 | 736.80K |
| Oct 2, 2026 | 15.05 | 15.16 | 14.31 | 14.99 | 948.50K |
| Oct 1, 2026 | 15.24 | 15.57 | 14.78 | 14.95 | 932.20K |
| Sep 30, 2026 | 15.80 | 15.99 | 15.14 | 15.33 | 1.43M |
| Sep 29, 2026 | 15.16 | 15.67 | 14.74 | 15.58 | 1.33M |
| Sep 28, 2026 | 15.47 | 15.47 | 14.97 | 15.08 | 749.60K |
| Sep 25, 2026 | 15.75 | 15.81 | 15.00 | 15.47 | 1.43M |
| Sep 24, 2026 | 15.24 | 16.10 | 14.58 | 15.72 | 1.90M |
| Sep 23, 2026 | 16.40 | 16.49 | 15.13 | 15.30 | 1.11M |
| Sep 22, 2026 | 16.44 | 16.86 | 16.28 | 16.51 | 585.50K |
| Sep 21, 2026 | 16.57 | 16.75 | 15.92 | 16.17 | 542.70K |
About Avalo Therapeutics
Avalo Therapeutics (AVTX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WAYNE, PA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1534120.
AVTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Mitchell Chan | Director | May 7, 2026 |
| Jonathan Goldman | Director | Mar 31, 2026 |
| Michael Thomas Heffernan | Director | Jun 4, 2026 |
| Rita Jain | Director | Jul 2, 2026 |
| Aaron Kantoff | Director | Jun 4, 2026 |
| Gilla Kaplan | Director | Jun 4, 2026 |
| Kevin Robert Lind | Director | Jul 2, 2026 |
| Garry Arthur Neil | Chief Executive Officer | May 26, 2026 |
| Ron M Philip | Director | Jul 2, 2026 |
| Samantha Truex | Director | Jun 4, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Taylor Boyd | Chief Business Officer | Mar 2, 2026 |
| Mittie Doyle | Chief Medical Officer | Sep 1, 2026 |
| Garry Arthur Neil | Chief Executive Officer | May 26, 2026 |
| Jennifer Riley | Chief Strategy Officer | Aug 12, 2026 |
| Christopher Ryan Sullivan | Chief Financial Officer | Sep 18, 2026 |
| Paul Varki | Chief Legal Officer | Jun 12, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 16, 2026 | Christopher Ryan Sullivan | Sale | 12,394 | $16.33 |
| Sep 16, 2026 | Christopher Ryan Sullivan | Sale | 12,394 | $16.33 |
| Sep 16, 2026 | Christopher Ryan Sullivan | Sale | 12,394 | $16.33 |
| Sep 16, 2026 | Christopher Ryan Sullivan | Sale | 12,394 | $16.33 |
| Sep 10, 2026 | Christopher Ryan Sullivan | Sale | 10,185 | $17.62 |
| Sep 10, 2026 | Christopher Ryan Sullivan | Sale | 10,185 | $17.62 |
| Sep 10, 2026 | Christopher Ryan Sullivan | Sale | 10,185 | $17.62 |
| Sep 10, 2026 | Christopher Ryan Sullivan | Sale | 10,185 | $17.62 |
| Aug 28, 2026 | Mittie Doyle | Sale | 679 | $20.00 |
| Aug 28, 2026 | Mittie Doyle | Sale | 679 | $20.00 |
| Aug 28, 2026 | Mittie Doyle | Sale | 679 | $20.00 |
| Aug 28, 2026 | Mittie Doyle | Sale | 679 | $20.00 |
| Aug 18, 2026 | Christopher Ryan Sullivan | Sale | 31,031 | $20.05 |
| Aug 18, 2026 | Christopher Ryan Sullivan | Sale | 31,031 | $20.05 |
| Aug 18, 2026 | Christopher Ryan Sullivan | Sale | 31,031 | $20.05 |
AVTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $59.00K | $-78.26M | -5.84 | $-51.46M |
| Dec 31, 2024 | $441.00K | $-35.13M | -20.91 | $-49.06M |
| Dec 31, 2023 | $1.92M | $-31.54M | -113.58 | $-30.68M |
| Dec 31, 2022 | $18.05M | $-41.66M | -1,063.00 | $-26.75M |
| Dec 31, 2021 | $5.40M | $-84.38M | — | $-70.89M |
Latest balance sheet: total assets $490.78M, total liabilities $42.12M, cash $85.38M (as of Jun 30, 2026).
AVTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $18.70 |
| May 13, 2026 | 8-K Item 2.02 (results) | $19.85 |
| May 7, 2026 | 8-K Item 2.02 (results) | $22.87 |
| Mar 23, 2026 | 8-K Item 2.02 (results) | $13.50 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $16.67 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $15.42 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $8.35 |
| May 12, 2025 | 8-K Item 2.02 (results) | $4.00 |
| Mar 20, 2025 | 8-K Item 2.02 (results) | $8.22 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $12.91 |
| Aug 12, 2024 | 8-K Item 2.02 (results) | — |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on AVTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.